1 In rat pulmonary artery pre-contracted with phenylephrine, the mechanisms of relaxation to the nitric oxide (NO) donor, spermine NONOate, were investigated. 2 Responses to spermine NONOate were only partially blocked by the soluble guanylate cyclase inhibitor, ODQ (1H-[1,2,4]Oxadiazolo-[4,3,-a]quinoxalin-1-one) at concentrations up to 30 muM. Ten muM ODQ gave maximal inhibition. Endothelium removal had no effect on the potency of spermine NONOate or its inhibition by ODQ. 3 The protein kinase G inhibitor, Rp-8-Br-cGMPS (100 muM), caused minimal inhibition of spermine NONOate despite causing marked inhibition of glyceryl trinitrate and isosorbide dinitrate. 4 Spermine NONOate (100 muM) caused a 35 fold increase in guanosine 3'5' cyclic mon...
I Vasorelaxant properties of three nitric oxide (NO) donor drugs (glyceryl trinitrate, sodium nitrop...
Preliminary experiments on isolated rat arteries demonstrated that thymoquinone, a compound widely u...
Compared to the currently available therapeutic drugs for peripheral vascular diseases, agents that ...
ODQ, (1H-[1,2,4]oxadiazolo][4,3-a]quinoxalin-1-one, an inhibitor of soluble guanylate cyclase) inhib...
The relative functional importance of potassium channels and cGMP-dependent pathways in the relaxati...
trosoglutathione, nitroprusside, glycerol tnnitrate, nitrite(allen dothelium-independent),bradykinin...
1 Inhibition of rat platelet aggregation by the nitric oxide (NO) donor MAHMA NONOate (Z-1-{N-methyl...
Authentic nitric oxide (NO; 0.1 - 10 micromoles) caused transient, dose-dependent relaxation of phen...
The aim of the present study was to investigate the actions of NO donors in ratsuperior mesenteric a...
Background. Many patients with severe acute lung injury do not respond to nitric oxide (NO) inhalati...
Recent work has indicated that prolonged treatment with nitric oxide (NO) donors results in tissue s...
The aim of this study was to investigate the mechanisms of relaxation to the nitric oxide (NO)-indep...
AIM: To study the interactions between prostacyclin and endothelium- derived nitric oxide in porcine...
The effects of authentic nitric oxide (NO, 10(-6) M) and NO-donors such as sodium nitroprusside (SNP...
BACKGROUND: Many patients with severe acute lung injury do not respond to nitric oxide (NO) inhalati...
I Vasorelaxant properties of three nitric oxide (NO) donor drugs (glyceryl trinitrate, sodium nitrop...
Preliminary experiments on isolated rat arteries demonstrated that thymoquinone, a compound widely u...
Compared to the currently available therapeutic drugs for peripheral vascular diseases, agents that ...
ODQ, (1H-[1,2,4]oxadiazolo][4,3-a]quinoxalin-1-one, an inhibitor of soluble guanylate cyclase) inhib...
The relative functional importance of potassium channels and cGMP-dependent pathways in the relaxati...
trosoglutathione, nitroprusside, glycerol tnnitrate, nitrite(allen dothelium-independent),bradykinin...
1 Inhibition of rat platelet aggregation by the nitric oxide (NO) donor MAHMA NONOate (Z-1-{N-methyl...
Authentic nitric oxide (NO; 0.1 - 10 micromoles) caused transient, dose-dependent relaxation of phen...
The aim of the present study was to investigate the actions of NO donors in ratsuperior mesenteric a...
Background. Many patients with severe acute lung injury do not respond to nitric oxide (NO) inhalati...
Recent work has indicated that prolonged treatment with nitric oxide (NO) donors results in tissue s...
The aim of this study was to investigate the mechanisms of relaxation to the nitric oxide (NO)-indep...
AIM: To study the interactions between prostacyclin and endothelium- derived nitric oxide in porcine...
The effects of authentic nitric oxide (NO, 10(-6) M) and NO-donors such as sodium nitroprusside (SNP...
BACKGROUND: Many patients with severe acute lung injury do not respond to nitric oxide (NO) inhalati...
I Vasorelaxant properties of three nitric oxide (NO) donor drugs (glyceryl trinitrate, sodium nitrop...
Preliminary experiments on isolated rat arteries demonstrated that thymoquinone, a compound widely u...
Compared to the currently available therapeutic drugs for peripheral vascular diseases, agents that ...